Hopman Mark 4
4 · Beta Bionics, Inc. · Filed Jun 5, 2026
Research Summary
AI-generated summary of this filing
Beta Bionics (BBNX) CCO Mark Hopman Sells 275 Shares
What Happened
Mark Hopman, Chief Commercial Officer of Beta Bionics (BBNX), sold 275 shares on 2026-06-04 at $12.31 per share, generating proceeds of approximately $3,385. The transaction is a sale (code S) and was reported on a Form 4 filed 2026-06-05.
Key Details
- Transaction date and price: 2026-06-04, 275 shares sold at $12.31 each.
- Total proceeds: ~$3,385.
- Sale executed pursuant to a Rule 10b5-1 plan adopted May 13, 2025 (footnote F1).
- Shares owned after the transaction: not specified in the provided filing excerpt.
- Filing timeliness: Form 4 was filed the next day (2026-06-05), consistent with SEC timeliness requirements.
Context
A sale under a Rule 10b5-1 plan is a pre-arranged trade and is often treated as routine rather than a direct signal of the insider's near-term view. Sales are generally less informative than purchases for gauging insider conviction.
Insider Transaction Report
Form 4
Hopman Mark
Chief Commercial Officer
Transactions
- Sale
Common Stock
[F1]2026-06-04$12.31/sh−275$3,385→ 130,612 total
Footnotes (1)
- [F1]Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025.
Signature
/s/ Stephen Feider, Attorney-in-Fact|2026-06-05